Home/Fosun Pharma/Wu Yifang
WY

Wu Yifang

Chairman of the Board

Fosun Pharma

Fosun Pharma Pipeline

DrugIndicationPhase
Yi Kai Da (Axicabtagene Ciloleucel)Relapsed/Refractory Large B-cell LymphomaApproved
Han Si Zhuang (Serplulimab)Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Approved
Su Ke Xin (Avatrombopag Maleate)Chronic Liver Disease-associated Thrombocytopenia (CLDT)Approved
Keverprazan HydrochlorideAcid-related Diseases (e.g., GERD)Phase III / NDA
Grafalon® (Anti-lymphocyte Globulin)Prophylaxis of Graft-versus-Host Disease (GvHD)Licensed
COMIRNATY® (BNT162b2)COVID-19 PreventionApproved
Novel Coronavirus Antigen & RT-PCR KitsCOVID-19 DiagnosisApproved